Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration

Table 2 Correlation of solute carrier family 2 member 1 and solute carrier family 2 expression and clinical prognosis in hepatocellular carcinoma with different clinicopathological factors in Kaplan-Meier plotter

Clinicopathological characteristics	Solute carrier family 2 member 1						Solute carrier family 2 member 2
	Overall survival			Relapse-free survival			Overall survival			Relapse-free survival
	n	Hazard ratio	P value	n	Hazard ratio	P value	n	Hazard ratio	P value	n	Hazard ratio	P value
Sex
Male	246	2.71 (1.73-4.24)	5.40E-06	210	1.36 (0.89-2.08)	0.149	246	0.3 (0.0.19-0.48)	5.80E-08	210	0.5 (0.34-0.75)	0.00068
Female	118	1.89 (1.06-3.38)	0.0287	106	1.61 (0.89-2.9)	0.1109	118	1.48 (0.75-2.93)	0.26	106	0.47 (0.26-0.85)	0.0108
Race
Asian	155	3.14 (1.71-5.77)	1.00E-04	143	1.54 (0.93-2.56)	0.092	155	0.2 (0.11-0.38)	3.80E-08	143	0.41 (0.23-0.73)	0.0017
White	181	1.98 (1.24-3.16)	0.0034	147	1.41 (0.88-2.27)	0.1527	181	0.61 (0.35-1.05)	0.072	147	0.53 (0.33-0.84)	0.0065
Black or African American	17	NA	NA	13	NA	NA	17	NA	NA	13	NA	NA
Sorafenib treatment
Yes	29	2.19 (0.61-7.89)	0.219	22	1.43 (0.59-3.47)	0.4312	29	0.23 (0.06-0.88)	0.0205	22	0.61 (0.24-1.53)	0.2867
None	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Risk factors
Alcohol consumption
Yes	115	1.94 (1-3.78)	0.0464	99	1.61 (0.86-3.03)	0.1365	115	0.42 (0.22-0.8)	0.0063	99	0.37 (0.2-0.67)	0.00061
None	202	2.34 (1.46-3.73)	0.00025	183	1.42 (0.9-2.23)	0.1284	202	0.41 (0.26-0.65)	9.70E-05	183	0.57 (0.34-0.96)	0.0337
Hepatitis virus
Yes	150	2.99 (1.5-5.95)	0.0011	139	1.45 (0.87-2.39)	0.149	150	0.32 (0.16-0.62)	0.0004	139	0.63 (0.37-1.05)	0.0749
None	167	2.39 (1.45-3.96)	0.00046	143	1.92 (1.12-3.32)	0.0168	167	0.47 (0.27-0.83)	0.0083	143	0.41 (0.25-0.68)	0.00038
Pathology
Stage
1	170	2.49 (1.33-4.64)	0.0031	153	1.67 (0.97-2.89)	0.0617	170	0.42 (0.22-0.77)	0.0044	153	0.41 (0.22-0.76)	0.0035
1+2	253	2.09 (1.27-3.44)	0.003	228	1.22 (0.8-1.86)	0.35	253	0.54 (0.33-0.87)	0.0107	228	0.4 (0.23-0.7)	0.00091
2	83	2.12 (0.79-5.64)	0.1258	75	0.5 (0.25-0.99)	0.0424	83	0.34 (0.1-1.14)	0.0665	75	0.56 (0.27-1.14)	0.1046
2+3	166	2.27 (1.39-3.7)	0.00072	145	1.44 (0.89-2.35)	0.1389	166	0.47 (0.26-0.83)	0.0077	145	0.65 (0.41-1.03)	0.064
3	83	2.78 (1.52-5.06)	0.00052	70	2.29 (1.21-4.3)	0.0086	83	0.31 (0.16-0.57)	0.00011	70	0.54 (0.29-0.99)	0.0428
3+4	87	2.67 (1.49-4.78)	6.00E-01	70	2.29 (1.21-4.3)	0.0086	87	0.34 (0.19-0.62)	0.0003	70	0.54 (0.29-0.99)	0.0428
4	5	NA	NA	0	NA	NA	4	NA	NA	0	NA	NA
Grade
1	55	0.67 (0.26-1.7)	0.3967	45	3.65 (0.83-16.1)	0.067	55	0.42 (0.14-1.27)	0.1114	45	0.45 (0.17-1.17)	0.0919
2	174	2.16 (1.29-3.61)	0.0025	149	1.49 (0.89-2.5)	0.1246	174	0.48 (0.28-0.81)	0.0051	149	0.48 (0.29-0.78)	0.0029
3	118	3.11 (1.69-5.7)	0.00012	107	2.16 (1.2-3.86)	0.0082	118	0.3 (0.14-0.66)	0.0014	107	0.62 (0.34-1,.14)	0.1221
4	12	NA	NA	11	NA	NA	12	NA	NA	11	NA	NA
American Joint Committee on Cancer system for tumor staging
1	180	2.31 (1.27-4.21)	0.0047	160	1.51 (0.89-2.58	0.1245	180	0.39 (0.22-0.71)	0.0014	160	0.41 (0.22-0.75)	0.0027
2	90	2.07 (0.79-5.44)	0.1303	80	0.48 (0.25-0.92)	0.023	90	0.45 (0.16-1.29)	0.1272	80	2.02 (0.9-4.56)	0.0836
3	78	3.04 (1.64-5.64)	0.00022	67	2.23 (1.11-4.48)	0.0209	78	0.29 (0.15-0.57)	0.00011	67	0.43 (0.22-0.83)	0.01
4	13	NA	NA	6	NA	NA	13	NA	NA	6	NA	NA
Vascular invasion
None	203	2.18 (91.26-3.78)	0.0043	175	1.32 (0.77-2.28)	0.3144	203	0.39 (0.23-0.66)	0.00027	175	0.45 (0.25-0.83)	0.0089
Micro	90	2.16 (1.01-4.62)	0.042	82	0.46 (0.24-0.88)	0.0163	90	0.32 (0.1-1.08)	0.0531	82	0.73 (0.37-1.44)	0.3593
Macro	16	NA	NA	14	NA	NA	16	NA	NA	14	NA	NA

NA: Not applicable.